268,541 Shares in MaxCyte, Inc. $MXCT Purchased by Nuveen LLC

Nuveen LLC bought a new position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 268,541 shares of the company's stock, valued at approximately $733,000. Nuveen LLC owned approximately 0.25% of MaxCyte as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mudita Advisors LLP lifted its stake in shares of MaxCyte by 2.2% in the fourth quarter. Mudita Advisors LLP now owns 3,223,407 shares of the company's stock worth $13,409,000 after buying an additional 69,966 shares in the last quarter. Chevy Chase Trust Holdings LLC lifted its stake in shares of MaxCyte by 66.5% in the first quarter. Chevy Chase Trust Holdings LLC now owns 2,230,182 shares of the company's stock worth $6,088,000 after buying an additional 890,353 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in MaxCyte by 15.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,429,071 shares of the company's stock valued at $5,945,000 after purchasing an additional 191,088 shares during the period. Gagnon Securities LLC lifted its position in MaxCyte by 431.3% during the first quarter. Gagnon Securities LLC now owns 1,048,318 shares of the company's stock valued at $2,862,000 after purchasing an additional 850,992 shares during the period. Finally, Royce & Associates LP lifted its position in MaxCyte by 30.1% during the first quarter. Royce & Associates LP now owns 1,040,873 shares of the company's stock valued at $2,842,000 after purchasing an additional 241,000 shares during the period. Institutional investors own 68.81% of the company's stock.

Insider Transactions at MaxCyte

In related news, CEO Maher Masoud bought 75,000 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was bought at an average cost of $1.37 per share, with a total value of $102,750.00. Following the completion of the purchase, the chief executive officer owned 175,000 shares of the company's stock, valued at approximately $239,750. The trade was a 75.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Stanley C. Erck bought 100,000 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The shares were bought at an average cost of $1.37 per share, with a total value of $137,000.00. Following the completion of the purchase, the director directly owned 398,328 shares of the company's stock, valued at $545,709.36. This represents a 33.52% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 355,000 shares of company stock valued at $479,950. Company insiders own 3.30% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. BTIG Research restated a "neutral" rating on shares of MaxCyte in a research report on Monday, August 11th. William Blair downgraded shares of MaxCyte from an "outperform" rating to a "market perform" rating in a research report on Thursday, August 7th. Wall Street Zen downgraded shares of MaxCyte from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, Stephens assumed coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $6.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.00.

MaxCyte Trading Up 3.7%

MXCT stock traded up $0.05 during midday trading on Friday, reaching $1.41. 488,207 shares of the company's stock traded hands, compared to its average volume of 1,038,944. The stock's 50-day moving average is $1.82 and its 200 day moving average is $2.37. The stock has a market cap of $150.32 million, a P/E ratio of -3.28 and a beta of 1.20. MaxCyte, Inc. has a 52-week low of $1.26 and a 52-week high of $5.20.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). The firm had revenue of $8.51 million during the quarter, compared to analysts' expectations of $9.57 million. MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%. As a group, research analysts expect that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.